Aradigm Corporation Revenue and Competitors
Estimated Revenue & Valuation
- Aradigm Corporation's estimated annual revenue is currently $10.1M per year. 0
- Aradigm Corporation's total funding is $27.1M.
Employee Data
- 00
Aradigm Corporation's People
| Name | Title | Email/Phone |
|---|
Aradigm Corporation Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $4.4M | 57 | -8% | $53M | N/A |
#2 | $21.2M | 137 | -26% | $110M | N/A |
#3 | $0.9M | 6 | 0% | N/A | N/A |
#4 | $2.3M | 15 | 15% | N/A | N/A |
#5 | $1.6M | 10 | -17% | N/A | N/A |
#6 | $0.7M | 9 | 50% | N/A | N/A |
#7 | $11.5M | 74 | -12% | N/A | N/A |
#8 | $0.4M | 275 | 10% | $236.7M | N/A |
#9 | $4M | 51 | -74% | $160M | N/A |
#10 | $2.3M | 15 | 15% | N/A | N/A |
What Is Aradigm Corporation?
Aradigm Corporation is a developer of advanced pulmonary drug delivery systems for the treatment of systemic conditions as well as lung diseases. The Company's hand-held AERx platform is being designed for the rapid and reproducible delivery of a wide range of pharmaceutical drugs and biotech compounds via the lung. The Company's non-invasive AERx systems have been shown in clinical studies to achieve performance equivalent to injection-based delivery systems. In addition, the Company's systems may improve therapeutic efficacy in cases where other existing drug delivery methods, such as pills, transdermal patches or inhalers, are too slow or imprecise.
keywords:N/A
$27.1M
Total Funding
N/A
Number of Employees
$10.1M
Revenue (est)
N/A
Employee Growth %
N/A
Valuation
N/A
Accelerator
Other Companies in Newark
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $300M | 0 | N/A | $14.5M |
#2 | N/A | 0 | N/A | N/A |
#3 | $0.1M | 1 | -80% | N/A |
#4 | $0.1M | 1 | -50% | N/A |
#5 | $0.1M | 1 | -67% | N/A |